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The role of de-prescribing in polypharmacy 
and inappropriate medication use
Impact of deprescribing dual-purpose 
medications on patient-related outcomes for 
older adults near end-of-life: a systematic 
review and meta-analysis
Shakti Shrestha , Arjun Poudel, Magnolia Cardona, Kathryn J. Steadman and Lisa M. 
Nissen
Abstract
Introduction: The decision to deprescribe medications used for both disease prevention and 
symptom control (dual-purpose medications or DPMs) is often challenging for clinicians. We 
aim to establish the impact of deprescribing DPMs on patient-related outcomes for older 
adults near end-of-life (EOL).
Methods: This systematic review was conducted according to the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) guideline. Literature was 
searched on PubMed, EMBASE, CINAHL, PsycINFO and Google Scholar until December 2019 
for studies on deprescribing intervention with a control group (with or without randomisation); 
targeting ⩾65-year olds, at EOL, with at least one life-limiting illness and at least one 
potentially inappropriate DPM. We were interested in any patient-related outcomes. Studies 
with similar outcome assessment criteria were subjected to meta-analysis and narrative 
synthesis otherwise. The risk of bias was assessed using Cochrane Risk of Bias and ROBINS-I 
tools for randomised controlled trials (RCTs) and quasi-experimental non-randomised 
controlled studies, respectively.
Results: Five studies covering 689 participants with mean age 81.6–85.7 years, the majority 
(74.6–100%) with dementia were included. The risk of bias was moderate to low. The 
deprescribing of DPMs lowered the risk of mortality (risk ratio (RR) = 0.59, 95% confidence 
interval (CI) = 0.44–0.79) and referral to acute care facilities (RR = 0.40, 95% CI = 0.22–0.73), 
but did not have a significant impact on the risk of falls, non-vertebral fracture, emergency 
presentation, unplanned hospital admission, or general practitioner visits. No significant 
difference was observed in the quality of life, physical and cognitive functions between the 
intervention and control groups.
Conclusion: There is some evidence that deprescribing of DPMs for older adults near the EOL 
can lower the risk of mortality and referral to acute care facilities, but there are insufficient 
good-quality studies powered to confirm a benefit in terms of quality of life, physical or 
cognitive function, health service utilisation and adverse events.
Plain Language Summary 
What is the health impact of withdrawal or dose reduction of medication used for disease 
prevention and symptom control in older adults near end-of-life?
Introduction: Older adults (aged ⩾ 65 years) with advanced diseases such as cancer, 
dementia, and organ failure tend to have a limited life expectancy. With the progression 
of these diseases towards the end-of-life, the intensity for day-to-day supportive care 
becomes increasingly necessary. The use of medications for symptom management is 
a critical part of such care, but the use of medications for long-term disease prevention 
Correspondence to: 
Shakti Shrestha  
School of Pharmacy, The 
University of Queensland, 
Pharmacy Australia Centre 
of Excellence, Level 
4, 20 Cornwall Street, 
Woolloongabba, Brisbane, 




Lisa M. Nissen  
School of Clinical 
Sciences, Queensland 
University of Technology, 
Brisbane, QLD, Australia
Magnolia Cardona  
EBP Professorial Unit, 




University, Gold Coast, 
QLD, Australia
Kathryn J. Steadman 
School of Pharmacy, The 
University of Queensland, 
Brisbane, QLD, Australia
1052343 TAW0010.1177/




Therapeutic Advances in Drug Safety 12
can become irrelevant due to the already shortened life expectancy and may become 
harmful due to alterations in physiology and pharmacology associated with age and 
frailty. This necessitates the withdrawal or dose reduction of inappropriate medications, 
the process called deprescribing. The decision to deprescribe medications used for both 
disease prevention and symptom control (DPMs) in this population is often challenging 
for clinicians. In this context, whether deprescribing of DPMs can improve patient-related 
health outcomes is unknown. 
Methods: Evidence from the literature was reviewed and analysed, and the quality of 
studies was assessed. Five studies were identified, which had 689 participants with an 
average age above 80 years and mostly suffering from dementia. 
Results: The analysis of these studies showed deprescribing of DPMs lowered the risk of 
death and referral to acute care facilities at 12 months but had no significant impact on 
falls, non-vertebral fractures, emergency presentations, unplanned hospital admission, 
general practitioner visits, quality of life, physical and mental functions. 
Conclusion: In conclusion, there were insufficient numbers of high-quality studies powered 
to confirm whether deprescribing of DPMs reduces adverse events, health service use, or 
improves the quality of life or functioning in older adults near the end of life.
Keywords: deprescribing, end of life, limited life expectancy, older adults, potentially 
inappropriate medication
Received: 7 May 2021; revised manuscript accepted: 14 September 2021.
Introduction
Older adults with life-limiting illnesses (LLIs) 
and limited life expectancy (LLE) frequently 
receive potentially inappropriate medications 
(PIMs),1,2 even in the last few months of their 
life.3,4 PIMs are often associated with poor health 
outcomes such as the increased risk of falls, rate 
of hospitalisation, the incidence of adverse drug 
events and risk of mortality while the decreasing 
quality of life (QOL).1,2,5,6 Older adults with LLIs 
are more vulnerable to poor outcomes, primarily 
due to alteration in pharmacology, as a result of a 
change in the body physiology7 and frailty-associ-
ated cachexia.8,9 Medication that was once bene-
ficial for disease prevention could be less relevant, 
and it may be more appropriate to taper or with-
draw such PIMs under the supervision of health-
care professionals, referred to as deprescribing.10
It is commonly acknowledged that the use of pre-
ventive medications for long-term benefits in 
older adults at the end-of-life (EOL) is inappro-
priate.1,2,11 For instance, statins are beneficial 
with at least two years of continuous use, but for 
short-term use, the risk of adverse drug events 
outweighs potential benefits.12,13 It is also known 
that people with LLIs and LLE often become 
clinically unstable at the terminal phase and 
symptoms could emerge at any time.14 At this 
point, proactive pharmacological management 
using symptom-control medicines becomes indis-
pensable. But some medications can have dual-
purpose, that is, they could be used for both 
disease prevention and symptom control. These 
medications are referred to in this review as dual-
purpose medications (DPMs). For example, 
hypoglycemic agents can be used for both short-
term and long-term risks of hyperglycemia,1 anti-
psychotics can be used for the symptom 
management of delirium at the EOL15,16 as well as 
in the treatment of behavioural and psychiatric 
symptoms of dementia (BPSD),17 diuretics are 
commonly used for the symptom management of 
dyspnoea due to pulmonary oedema at the 
EOL18,19 and also for the secondary prevention of 
chronic heart failure.20 Deprescribing such medi-
cations in the clinical setting can be complex and 
challenging to consider due to the patient resist-
ance to discontinuation combined with multiple 
specialists having oversight for the care of patients 
with multiple co-morbidities.21 Moreover, clini-
cian’s decisions on deprescribing can be compli-
cated by uncertainty around disease prognosis 
with the changing goal of care towards the 
EOL.22,23 Evidence from a recent systematic 
review suggests that deprescribing preventive 
medications at the EOL improves medication 
appropriateness and has potential for improved 
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health outcomes,24 but whether deprescribing 
DPMs improve patient outcomes is unclear. This 
review aimed to fill that knowledge gap by explor-
ing the impact of deprescribing potentially inap-
propriate DPMs on patient-related outcomes for 
older adults with LLIs and LLE to assist clini-
cians’ decisions.
Methods
The reporting of this study was per the Preferred 
Reporting Items for Systematic Reviews and 
Meta-Analyses statement. The protocol was reg-
istered in the Open Science Framework (https://
osf.io/ur73q/).25 The definitions of key terms used 
in this review are provided below.
 • Deprescribing: Tapering or withdrawal or 
discontinuation of an inappropriate medi-
cation, supervised by a healthcare profes-
sional, with the goal of reducing or 
managing polypharmacy and improving 
patient outcomes.10
 • PIMs: Medicine(s) or medication class(es) 
that should generally be avoided in ⩾65 
years either due to their ineffectiveness or 
unnecessarily high risk for an older person 
or when a safe alternative is available for a 
similar disease condition. PIM identified 
with any explicit and implicit criteria was 
included in this study.24,26
 • DPMs: Medications used for both preven-
tion and symptom control identified in 
older adults with LLE. A list of DPMs gen-
erally known to be used in older adults with 
LLE has been obtained from previous 
studies.1,27–29
 • LLI: Terminal illness that limits life expec-
tancy, such as the advanced or end-stage 
condition of cancer, dementia, heart fail-
ure, chronic obstructive pulmonary disease 
and kidney disease.
 • EOL: EOL is a period preceding an indi-
vidual’s natural death from a process that is 
unlikely to be arrested by medical care, with 
LLE. A patient with at least one LLI with 
an irreversible decline and life expectancy 
of less than or equal to 12 months was con-
sidered to be at EOL in this review. 
However, studies using terms such as ter-
minally ill, terminal illness, under palliative 
care or frail were also considered as being 
EOL-relevant when the life expectancy was 
not specified. EOL was considered based 
on Criteria for Screening and Triaging to 
Appropriate aLternative care (CriSTAL or 
CrisTAL criteria)30 if the target popula-
tion’s mean age was ⩾80 years and met at 
least two criteria, or if the target popula-
tion’s mean age was ⩾65 years and met at 
least four criteria, these participants were 
deemed to be at the EOL.
 • Patient-related outcomes: Our inclusion 
criteria considered patient-related out-
comes as any clinical or patient-reported 
measures, such as QOL, short-term mortal-
ity, falls, hospital referral or admission, 
emergency presentations, fractures, or 
medication-related adverse effects within 
12 months.
 • Impact: Any change in the estimate of a pri-
mary outcome (in any unit) following the 
intervention was defined as impact.
Study selection
PubMed, Embase, Cumulative Index to Nursing 
and Allied Health Literature, PsycINFO and 
Google Scholar were searched for eligible articles 
from inception to December 2019 in English. 
Keywords and controlled vocabulary were used 
with appropriate Boolean logics, synonyms, and 
limiters (Supplementary Table S1 for literature 
search strategy for more details). The bibliogra-
phies of relevant reviews were manually assessed 
for additional references. Duplicate articles were 
located and removed in Endnote software, fol-
lowed by Covidence software and then manually. 
The target population was patients in any setting 
with an average age of ⩾65 years, at the EOL due 
to any LLI, prescribed with at least one potentially 
inappropriate DPM (Supplementary Table S2 for 
list of DPMs) and receiving any type of strategy to 
deprescribe such medications. For articles poten-
tially eligible on the title and abstract but not speci-
fying EOL or equivalent keywords or life 
expectancy, the full texts were assessed for the 
EOL definition using a validated tool called 
Criteria for Screening and Triaging to Appropriate 
aLternative care (CriSTAL criteria) for high risk of 
short-term death.30 Any controlled intervention 
(tool or guideline) targeted at deprescribing in 
older patients at home, pharmacy, clinics, nursing 
homes, residential aged care facilities (RACFs), 
and hospitals was included. Articles not reporting 
on any patient-related outcomes or where it was 
unclear whether patients were at the EOL were 
excluded. Conference proceedings, review articles, 
4 journals.sagepub.com/home/taw
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unpublished literature, before-after interventions 
and any ongoing studies were excluded. Two 
authors (SS and AP) independently performed the 
initial screening of the title and abstract followed 
by full-text assessment. Any disagreements were 
resolved with a consensus involving additional 
evaluation by the other authors.
Data extraction
A purpose-built data extraction form was used to 
collect data on design, demographics, life expec-
tancy, LLIs, settings, sample size, follow-up 
period, PIM assessment tools, potentially inap-
propriate DPMs targeted/deprescribed and their 
therapeutic categories, deprescribing interven-
tions and intervention providers, comparator and 
outcomes. Corresponding authors of eligible 
publications were approached for missing or 
ambiguous information, where necessary. Two 
authors (SS and AP) independently conducted 
data extraction and agreed on consensus basis.
Risk of bias assessment
Cochrane risk of bias tool and Risk Of Bias In 
Non-randomised Studies of Interventions 
(ROBINS-I) were used by two authors (SS and 
AP) independently to assess the risk of bias for 
randomised controlled trials (RCTs) and quasi-
experimental non-RCTs, respectively.
Data synthesis and analysis
A narrative synthesis of data was conducted for all 
outcome measures with a calculated 95% confi-
dence interval (CI) around the published esti-
mates. Meta-analyses of selected homogeneous 
outcome measures used the random-effects model 
to pool the risk ratios (RRs) and 95% CIs using 
RStudio version 1.3.959 (PBC, Boston MA).
Ethics statement
Our study did not require an ethical board 
approval because we reviewed previously pub-
lished studies that are publicly accessible, and 
each of the included studies stated that an ethics 
approval was obtained.
Results
A total of 10,826 studies (PubMed: 4381, 
Embase: 2143, CINHAL: 1140, PsycINFO: 
3055, Google Scholar: 105, Other sources: 2) 
were identified and after removal of duplicates, 
9247 studies were screened for the title and 
abstract, leading to 56 for full-text eligibility; 5 
met the criteria for inclusion (Figure 1).
Five studies31–35 conducted in the United 
Kingdom,31 Belgium,32 Israel,33 Australia,34 and 
Norway35 were included in this systematic review. 
There were four RCTs31,32,34,35 and one quasi-
experimental study33 involving 689 participants 
(mean age: 81.6–85.7 years) with 3–12 months 
follow-up and conducted in a hospital setting 
(n = 3)31–33 or RACFs (n = 2).34,35 Majority of par-
ticipants were female (52%34–75%)35 and had 
dementia. Except for one study on deprescribing 
of only anti-depressants,35 other studies assessed 
PIMs using either validated explicit criteria, such 
as STOPPFrail (Screening Tool of Older Persons 
Prescriptions in Frail adults with LLE)31 and 
STOPP (Screening Tool of Older Persons’ 
Prescriptions)32 or using a specifically developed 
list of PIMs34 or algorithm33 for the study.
Deprescribing interventions and intervention 
providers
The deprescribing interventions were either active 
deprescribing33–35 or indirect deprescribing (rec-
ommendation),31,32 but there was either with-
drawal, cessation, tapering or discontinuation of 
medication after the intervention (Table 1). The 
intervention providers were either physician/geri-
atrician31–33 or multidisciplinary team.34
The three studies which involved an active depre-
scribing intervention are described below.
 • Identification of medications suitable for 
dose reduction or discontinuation using a 
geriatric-palliative criterion (algorithm), led 
by a physician.33 The algorithm considered 
risk-benefit evaluation based on indication, 
dosing rate, age, frailty and adverse effects 
on an evidence-based consensus to either 
stop, change, reduce the dose or continue 
the medication.
 • An individualised medication review fol-
lowed by a planned cessation of non-bene-
ficial medications by a general practitioner 
(GP) and a geriatrician/clinical pharmacol-
ogist.34 The medication review identified 
target medications for withdrawal that 
S Shrestha, A Poudel et al.
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included inappropriate medications, medi-
cations with no symptom benefits but with 
possible or potential adverse drug with-
drawal event (ADWE) and medications 
with symptomatic benefit (symptom being 
stable). The target medications were tested 
against deprescribing criteria (algorithm) 
using baseline data.
 • Tapering off and replacement of escitalo-
pram, citalopram, sertraline and paroxetine 
(selective serotonin reuptake inhibitors or 
SSRIs) by a placebo over the first week after 
baseline assessment.35 Information on the 
intervention provider was not provided but 
the intervention was assigned randomly.
The two studies that followed an indirect depre-
scribing intervention are discussed below.
 • An individualised withdrawal plan for a 
pre-determined medication with possible 
ADWE and unlikely ADWE, guided by 
STOPPFrail criteria was formulated by a 
research physician to make a recommenda-
tion to the attending physician. Also, a 
restarting plan was provided.31 The recom-
mendation was documented in the patient 
medical record and communicated to the 
attending physician, who decided whether 
or not to implement the recommended plan 
and changes.
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of the 
screening process.
6 journals.sagepub.com/home/taw
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Table 1. Characteristics of study participants and deprescribing interventions.






Other profile Inclusion criteria Deprescribing intervention
Curtin et al.31 Hospital
RCT
130 a85.1 years., 
61.5% female
a74.6% dementia, 
a23.9% CKD, a8.5% 
active cancer, frail




An individualised withdrawal 
plan guided by STOPPFrail 
for use by the physician.
Follow-up: 3 months
Dalleur et al.32 Hospital
RCT
146 Median age 





CVD, all had a 
frail profile and 
geriatric syndrome
Age ⩾ 75 years, risk of 
frailty, admission to the 
medical ward, availability 
of a CGA
STOPP recommendations 
made by IGCT to ward 
physicians to discontinue 













Frail elderly Geriatric-palliative approach 
algorithm led by a physician
Follow-up: 12 months
Potter et al.34 RACF
RCT









review followed by stopping 
non-beneficial medications 
conducted by a GP and a 
geriatrician/CP
Follow-up: 6 and 12 months
Bergh et al.35 RACF
RCT
128 a85.7 years, 
75% female
All dementia Nursing home residents 
for >4 weeks, diagnosed 
with dementia, had 
a neuropsychiatric 
symptom, prescribed an 
SSRI for at least 3 months
Discontinuation of anti-
depressants (escitalopram, 
citalopram, sertraline or 
paroxetine)
Follow-up: 4, 7, 13 and 25 
weeks
Abbreviations: CGA, comprehensive geriatric assessment; CKD, chronic kidney disease; CP, clinical pharmacologist; CVD, cardiovascular disease; 
GP, general practitioner; IGCT, inpatient geriatric consultation team; PIMs: potentially inappropriate medications; RACF, residential aged care 
facility; RCT, randomised controlled trial; SSRIs, selective serotonin reuptake inhibitors; STOPP, Screening Tool of Older Persons Prescriptions; 
STOPP-Frail, Screening Tool of Older Persons Prescriptions in Frail adults with a limited life expectancy.
aCalculated from the data in the study.
bInformation provided by the corresponding author.
 • Oral and written recommendations made 
to ward physicians by two geriatricians to 
discontinue PIMs identified by systemati-
cally screening the list of medications taken 
by patients on admission through the use of 
64 STOPP criteria.32
Comparator
The comparators in all the studies were the con-
trol groups, which received one of the following:
 • Usual pharmaceutical care, that is, hospital 
physician and pharmacist care.31 This study 
used an individualised withdrawal plan 
guided by the STOPPFrail criteria in the 
intervention group.
 • Usual care but were visited as frequently as 
the intervention group. On each visit, their 
blood pressure was measured and signifi-
cant concerns were reported to nursing staff 
for appropriate follow-up.34 This study 
used an individualised medication review 
followed by a planned cessation of non-
beneficial medications in the intervention 
arm.
 • No placebo but continued with the same 
anti-depressant.35 The group that received 
placebo (intervention) had their SSRIs 
tapered off and replaced by a placebo 
over the first week after baseline 
assessment.
 • Standard care from inpatient geriatric con-
sultation team involving two geriatricians 
without previous experience with STOPP 
criteria.32 The intervention group had two 
geriatricians who used 64 STOPP criteria 
to deprescribe PIMs.
S Shrestha, A Poudel et al.
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 • No changes in medication but hospitalised 
in the same departments and treated by the 
same team.33 The study used a geriatric-
palliative algorithm to deprescribe in the 
intervention group.
The components of “usual care” or “standard 
care” were not generally described in the 
studies.
Targeted and deprescribed DPMs
Overall, the included studies targeted 404 
DPMs for deprescribing (Table 2). These were 
primarily central nervous system medications 
(anti-depressants, n = 10932–35; anti-psychotics, 
n = 3131,33,34 and anti-dementia medication, 
n = 7),31,34 gastrointestinal medications (drugs 
used for acid-related disorder, n = 8331,33,34; and 
laxatives, n = 43)31,34 and cardiovascular medi-
cations (anti-hypertensive, n = 6031,33; diuretics, 
n = 3633,34; nitrates, n = 2233; and beta-blockers, 
n = 16).32,34 The overall success of deprescribing 
was 75.7% but it varied between 33.3% for 
beta-blockers32,34 to 100% for nitrates.33 The 
highest rate of successful deprescribing of anti-
depressants at 6.25 months (92.1%) was 
observed in the study that involved tapering off 
and replacing four SSRIs with a placebo over 
the first week.35 This study did not involve 
deprescribing of other medications except the 
SSRIs. Among other studies, the next most suc-
cessful deprescribing (86.4% at 3 months) was 
observed in a study that utilised an individual-
ised withdrawal plan based on STOPPFrail cri-
teria formulated by a research physician and 
recommended to the attending physician.31 This 
study had 77.8% success of deprescribing of 
anti-psychotics to 87.8% average success of 
deprescribing of all targeted medications includ-
ing anti-dementia medication, laxatives, anti-
hypertensive, oral hypoglycemic agents and 
anti-histamines at 3 months. Another study that 
used a geriatric-palliative algorithm had an 
overall 84.5% success on deprescribing several 
DPMs at 12 months but better success on 
deprescribing of nitrates (100%), diuretics 
(85.2%), anti-hypertensive (84.3%)] and medi-
cation for the acid-related disorder (94.3%).33 
The other study that involved an individualised 
medication review followed by a planned cessa-
tion of non-beneficial medicines by a GP and a 
geriatrician/clinical pharmacologist had an 
overall 51.1% rate of success at 12 months.34 
The remaining study that involved identifica-
tion of PIMs by two geriatricians using 64 
STOPP  criteria and recommending them to the 
ward physicians, had 60% and 16.7% success in 
deprescribing anti-depressants and beta-block-
ers, respectively, at discharge.32
The following sections detail the impacts of the 
deprescribing intervention on QOL, mortality, 
adverse events and health service utilisation.
Patient-related outcome measures
 • QOL: Three RCTs reported on QOL 
(Table 3). One study31 assessed QOL 
through scores derived from the 
QUALIDEM (QOL instrument for proxy 
completion) instrument at 3 months. This 
study showed that the baseline score 
(Intervention group (I): 6.96, Control 
group (C): 7.58) declined at 3 months (I: 
–2.43, C: –2.85) but there was no signifi-
cant difference between the two groups 
(p = 0.60). The remaining two studies used 
QOLAD (QOL in Alzheimer’s Dementia) 
tool for assessing QOL. One of these stud-
ies,35 which specifically deprescribed anti-
depressants, reported a decline of the score 
in the intervention group but a rise in the 
control group (I: –0.87, C: 1.49, p = 0.314) 
at 6.25 months (25 weeks). The other 
study34 showed a decline of the score by 
one unit in both the groups at 12 months 
(p = 0.91). However, the baseline and 12 
months QOLAD scores in both of these 
studies34,35 were above 30 (good QOL) in 
the two groups.
 • Physical and cognitive functioning: Two 
studies34,35 reported on the functional status 
and found no significant differences in 
either the physical or cognitive functions 
between the intervention and control groups 
at 6.2535 and 12 months34 (Table 3). For 
assessing physical function, the Lawton and 
Body’s Physical Self-Maintenance Scale 
score (I: 18.5 vs C: 18.1)35 or the modified 
Barthel Index (MBI) score (I: 38 vs C: 4)34 
was used. For assessing cognitive function, 
severe impairment battery scale score (I: 73 
vs C: 68)35 and mini–mental state examina-
tion or MMSE score (I: 12, C: 11)34 were 
used.
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Curtin et al.31 Dalleur et al.32 Garfinkel et al.33 Potter et al.34 *Bergh et al.35
T S T S T S T S T S T S
Anti-depressants – – 5 60 19 73.7 22 36.4 63 92.1 109 65.5
Anti-psychotics 9 77.8 – – 13 69.2 9 66.7 – – 31 71.2
Anti-dementia 4 a87.8 – – – – 3 66.7 – – 7 77.2
Medication for acid-
related disorder (H2 
blockers and PPIs)
26 a87.8 – – 35 94.3 22 59.1 – – 83 80.4
Laxatives 7 a87.8 – – – – 36 27.8 – – 43 57.8
Anti-hypertensive 9 a87.8 – – 51 84.3 – – – – 60 86.1
Diuretics – – – – 27 85.2 – – – – 27 85.2
Nitrates – – – – 22 100 – – – – 22 100
Beta-blockers – – 6 16.7 – – 10 50 – – 16 33.3
Oral hypoglycemic 
agents
3 a87.8 – – – – – – – – 3 87.8
Anti-histamines 3 a87.8 – – – – – – – – 3 87.8
Overall 61 86.4 11 38.4 167 84.5 102 51.1 63 92.1 404 75.7
Abbreviations: PPIs, Proton Pump Inhibitors; S, successful deprescribing percentage; SSRIs, selective serotonin reuptake inhibitors; T, targeted 
number of dual-purpose medications.
aAverage successful deprescribing of all the targeted medications that included medications other than dual-purpose medications.
*Only targeted SSRIs (escitalopram, citalopram, sertraline and paroxetine).
Table 3. Impact of deprescribing of dual-purpose medications on patient-related outcomes according to follow-up duration. 
Outcome measures Author(s) Follow-up duration Sample attrition Outcomes
<12 m 12 m I C I C p-Value
Quality of life scores Curtin et al.31 3 m – 37/65 38/65 4.53 ± 4.23 4.73 ± 4.30 0.790
Bergh et al.35 6.25 – 20/63 31/65 32.8 ± 7.1 35.9 ± 5.0 0.314
Potter et al.34 6 m 12 m 22/47 15/48 a32.0 ± 4.3 a31.0 ± 4.7 0.940
Physical function scores Potter et al.34 6 m 12 m 34/47 30/48 a38 ± 18 a34 ± 17 0.760
Bergh et al.35 6.25 – 35/63 46/65 18.5 ± 5.6 18.1 ± 5.4 0.915
Cognitive function scores Potter et al.34 6 m 12 m 34/47 30/48 a12 ± 5 a11 ± 4 0.540
Bergh et al.35 6.25 – 23/63 37/65 73.4 ± 24.0 68.0 ± 30.9 0.956
Depression Bergh et al.35 6.25 – 31/63 46/65 6.03 ± 4.76 4.42 ± 3.77 0.045*
(Continued)
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Outcome measures Author(s) Follow-up duration Sample attrition Outcomes
<12 m 12 m I C I C p-Value
Mortality Curtin et al.31 3 m – 65/65 65/65 18.5% 27.7% 0.220
Dalleur et al.32 – 12 m 39/77 37/81 a10.4% a9.9% NR
Garfinkel et al.33 – 12 m 119/119 71/71 21.0% 45.0% <0.001*
Potter et al.34 6 m 12 m 47/47 48/48 25.5% 39.6% 0.160
Falls Curtin et al.31 3 m – 52/65 47/65 27.5% 29.8% 0.750
Potter et al.34 6 m 12 m 45/47 48/48 55.6% 64.6% 0.400
Non-vertebral fracture Curtin et al.31 3 m – 52/65 47/65 1.9% 8.5% 0.180
Potter et al.34 6 m 12 m 45/47 48/48 6.7% 4.2% 0.670
Unplanned hospital 
admission
Curtin et al.31 3 m – 65/65 65/65 13.8% 7.7% 0.270
Potter et al.34 6 m 12 m 45/47 48/48 51.1% 50.0% 0.990
Emergency presentations Curtin et al.31 3 m – 65/65 65/65 4.6% 7.7% 0.720
GP visits Potter et al.34 6 m 12 m 45/47 48/48 22.2% 10.4% 0.160
Referral to acute care 
facilities
Garfinkel et al.33 – 12 m 119/119 71/71 11.8% 30.0% <0.002*
QOL was measured by QUALIDEM31 and QOLAD (total score: 52)34,35; Physical function was measured by MBI (total score: 100)34 or Lawton & Body’s 
Physical Self-Maintenance Scale35; Cognitive function was measured by MMSE (total score: 30)34 or Severe impairment battery scale.35
Abbreviations: C, control group; d, Day; GP, general practitioner; I, intervention group; m, Month; MBI, Modified Barthel Index; MMSE, Mini–Mental 
State Examination; NR, not reported; QOL, quality of life: QOLAD, Quality of Life in Alzheimer’s Dementia; QUALIDEM, quality of life instrument for 
proxy completion; wk, Week.
aCalculated from the data given in the study.
*Statistically significant.
Table 3. (Continued)
 • Mortality: The four studies reporting on 
mortality31–34 showed that it varied greatly 
(absolute risk difference of 0.532–24.0%33 at 
12 months) through 9.2% at 3 months 
between intervention and control groups. 
However, only the largest study with a 
12-month follow-up reported that the dif-
ference was statistically significant 
(p < 0.001)33 (Table 3). The forest plot in 
Figure 2 showed that deprescribing using a 
geriatric-palliative algorithm significantly 
reduced the risk of mortality at 12 months 
in the intervention group by 53% when 
compared to the control group that had no 
changes in their medication (RR, 0.47; 95% 
CI, 0.30–0.72). Analysis of the overall 
impact on mortality through the random 
effect model from the four studies31–34 
(Figure 2 and Table 3) suggested that 
deprescribing of DPMs (not limited to the 
geriatric-palliative algorithm) also signifi-
cantly reduce the risk of mortality in the 
intervention group by 41% (RR, 0.59; 95% 
CI, 0.44–0.79) within 12 months compared 
to the control group (usual care or standard 
care or no change in the medication).
 • Falls: Three studies31,34,35 reported the adverse 
outcome of falls. A meta-analysis of the 
overall impact of deprescribing on falls based 
on two studies (Figure 2 and Table 3) 
showed no significant reduction in the risk of 
falls at 3 or 12 months after the intervention 
(RR, 0.87; 95% CI, 0.65–1.17). The third 
study35 reported that the mean ± SD change 
in the number of falls per day in 21 days was 
similar (I: 0.01 ± 0.02 vs C: 0.01 ± 0.03).
10 journals.sagepub.com/home/taw
Therapeutic Advances in Drug Safety 12
 • Non-vertebral fractures: This adverse event 
was reported by two studies31,34. The over-
all impact of deprescribing on non-vertebral 
fractures (Figure 2 and Table 3) showed 
that the risk of this adverse event was not 
reduced significantly after the intervention 
either at 3 or 12 months (RR: 0.67; 95% 
CI: 0.10–4.56).
 • Unplanned hospital admission: Two stud-
ies reported on this outcome at 3 months31 
and 12 months34 and found that the overall 
impact of deprescribing (Figure 2 and 
Figure 2. Random effect models and forest plots showing the impact of deprescribing of dual-purpose 
medications on mortality, adverse events and healthcare utilization: (a) impact on mortality. (b) Impact on falls. 
(c) Impact on non-vertebral fractures. (d) Impact on unplanned hospital admission.
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Table 3) showed the risk of unplanned hos-
pital admission was not different between 
the intervention group compared to the 
control group (RR: 1.12; 95% CI: 
0.74–1.69).
 • Emergency presentation: One study that 
reported on emergency presentations at 3 
months31 found that the risk of this event in 
the intervention group was not significantly 
different from that of the control group 
(RR: 0.60; 95% CI: 0.15–2.41; Table 3).
 • GP visits: This outcome was reported by 
one study34 and the analysis of data showed 
that the risk at either 6 or 12 months was 
not different between the intervention and 
the control group (Table 3).
 • Referral to acute care facilities: This event 
was reported by one study,33 and it found 
that the deprescribing intervention group 
using the geriatric-palliative algorithm had 
a significantly lower 12-month referral rate 
to acute care facilities than the control 
group that had no change in their medica-
tions (11.8% vs 30.0%, p = 0.002; RR, 
0.40; 95% CI, 0.22–0.73; Table 3).
 • Other patient-related outcomes: Other 
patient-related outcomes were reported by 
two studies34,35 that included 12 months 
follow-up of sleep quality34; and three 
months follow-up of depression,35 neu-
ropsychiatric symptoms,35 extrapyramidal 
side effects35 and body weight.35 No signifi-
cant difference was reported in these out-
comes except for depression in the 3-month 
follow-up study. This study involved taper-
ing off and replacing escitalopram, citalo-
pram, sertraline and paroxetine with 
placebo over the first week and reported 
significantly higher Cornell scores for 
depression in the intervention group than 
the placebo control group (6.03 ± 4.76 vs 
4.42 ± 3.77; p = 0.045).35
Risk of bias
The risk of bias of all four RCTs31,32,34,35 was 
assessed using the Cochrane Risk of Bias Tool. 
The overall risk of bias of included studies was 
moderate to low (Supplementary Table S3 and 
S4). All the studies had a low risk of bias only on 
blinding of outcome assessors and half of the 
studies had not blinded participants and adminis-
tering personnel as well as had incomplete out-
come data. Three of the four studies had ensured 
randomisation, concealment allocation, and 
avoided selective reporting of the outcome. But 
all studies had one or more other sources of bias, 
including inclusion bias,35 bias due to sample 
size,31,34 respondent bias,34 contamination 
bias31,32 and bias on the readiness of implement-
ing the deprescribing recommendation.31 The 
remaining one quasi-experimental study33 was 
assessed using the ROBINS-I tool and the overall 
risk of bias for this study was serious. Although 
most of the items had a low risk of bias in this 
study, serious concerns arose for confounding 
and selection.
Discussion
This review on deprescribing interventions 
involving DPMs for older people with LLI near 
the EOL in hospitals and RACFs found a sub-
stantial reduction in 12-month mortality 
(RR = 0.59), 12-month referral to acute services 
(60% decrease), and worsening of depression 
scores (rise by 1.61, p = 0.045). The included 
deprescribing interventions failed to demonstrate 
reductions in either health service utilisation, or 
adverse events such as falls, or improvements in 
QOL or cognitive/physical functioning, but small 
sample sizes of most studies with associated lack 
of power may have contributed to this shortcom-
ing. An important finding of this review was the 
scarcity of studies investigating DPMs and tar-
geting people near the EOL. Given the projected 
increase in both the proportion of older adults 
and the escalating prevalence of dementia over 
the next three decades, these findings call for the 
investigation of these issues as a matter of 
priority.
The approach to deprescribing intervention in 
each study varied but in general was either active 
deprescribing or recommendation by a variety of 
health professional teams – physician/geriatrician, 
or multidisciplinary team of GP and geriatrician 
or clinical pharmacologist. While this may reflect 
locally relevant practice, it limits the comparabil-
ity of effectiveness estimates.
This review suggested a general decline in the 
QOL irrespective of its state (good or poor), types 
of deprescribing and whether deprescribing was 
performed. The QOL did not differ significantly 
between intervention and control groups for up to 
12 months. A systematic review on a similar pop-
ulation also concluded that the QOL may not 
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improve significantly,36 but the data were hetero-
geneous and medications were not categorised 
into preventive, symptom control or dual-pur-
pose, whereas our review excluded studies exclu-
sively on preventive and symptom-control 
medications. Another systematic review on depre-
scribing of anti-psychotics in older adults with 
dementia found low or no clear evidence on 
QOL.37 In our review, data on QOL could not be 
pooled because the included studies had hetero-
geneity in terms of the assessment tool, DPMs 
deprescribed and follow-up periods. Particularly 
concerning was the overall impact of high sample 
attrition (38.934–57.7%)31 on the reliability of the 
QOL measure.
Deprescribing interventions appear to generate 
no significant alteration to physical and cogni-
tive function at 6.25 and 12 months. The tool 
used for the assessment of both the functions 
varied in the included studies, therefore, data 
were not pooled. Most participants included in 
the studies of our review had dementia. People 
with dementia are known to have a gradual and 
prolonged decline in their functional capacity in 
long-term care and palliative care.38 The ability 
of current treatments to slow down the func-
tional deterioration in LLIs and EOL is rather 
limited, but a systematic review has indicated 
accelerated cognitive decline in dementia 
patients on benzodiazepines39; by implication, 
deprescribing could be hypothesised to improve 
cognitive and functional capacity. In our review, 
however, the findings showed that functional 
capacity did not differ significantly after 
deprescribing.
In this review, three31,33,34 of the four31–34 studies 
reported on mortality showing a non-significant 
effect of deprescribing. However, the overall risk 
of mortality in the intervention group was lower 
compared to the control group in hospitals and 
RACFs when the pooled data derived from the 
meta-analysis of the four studies was considered. 
Meta-analysis utilises the data pooled from the 
individual studies, which can increase the statisti-
cal power and has been proven useful when indi-
vidual studies are not sufficiently powered due to 
a small sample size.40,41 Previous systematic 
reviews of deprescribing of PIMs in older adults, 
not necessarily at the EOL, had shown similar 
results irrespective of LLIs,24,42,43 but the focus of 
those reviews were not on DPMs.
The outcomes on the risk of falls were reported to 
be non-significant by the two RCTs,31,34 but the 
authors reported the possibility that they were 
underpowered to detect significant changes in 
these outcomes. While recent studies have found 
that DPMs, such as anti-psychotics, digoxin and 
diuretics,44–46 may increase the risk of falls, our 
study could not confirm this. Referral to acute 
care facilities reported by the quasi-experimental 
study,33 showed significantly lower referrals in the 
intervention group than the control group.
The list of DPMs considered by our review was 
generated from the literature; diuretics and anti-
psychotics are particularly worthy of discussion 
here. Diuretics, particularly furosemide are com-
monly prescribed until the last month of life in 
patients with terminal illnesses,18,28 most likely to 
manage symptoms such as dyspnoea secondary to 
pulmonary oedema.18,19 This is particularly 
important in patients with advanced heart failure, 
even towards the EOL.18,47 Diuretics are also 
used for the secondary prevention of disease but 
when the time-until-benefit is less than the esti-
mated life expectancy, it could be reasonable to 
deprescribe diuretics used for the preventive 
measure.28 Two studies included in our review 
reported 76% overall successful deprescribing of 
diuretics; one study stated recurrence of symp-
toms/signs as the cause of failure and the drug 
was re-administered,33 and the other study stated 
that while not all targeted diuretics were depre-
scribed those that were attempted had 100% suc-
cess.34 However, neither study identified whether 
the diuretics were indicated for oedema, advanced 
heart failure or hypertension, or if they were used 
for the secondary prevention of disease. Anti-
psychotics were deprescribed with just over 70% 
overall success.31,33,34 Anti-psychotics are com-
monly used in older adults with LLE47–49 and 
have played a significant role in the symptom 
management of delirium.15,16,28 Haloperidol has 
also been used for management of psychosis, ter-
minal agitation/restlessness, nausea and vomiting 
at the EOL but requires close monitoring of 
extrapyramidal side effects.16 For the manage-
ment of BPSD, the STOPPFrail13 and its update 
STOPPFrail version 250 recommend deprescrib-
ing neuroleptic anti-psychotics in those taking 
these medications for more than 3 months if there 
are no symptoms of BPSD. One of the three stud-
ies included in this review used STOPPFrail cri-
teria13 for deprescribing of anti-psychotics. The 
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other two studies considered a risk/benefit assess-
ment and where necessary tapering dose and/or 
monitoring for adverse withdrawal effects and/or 
considering alternative medication, although nei-
ther clarified whether the anti-psychotic was used 
for BPSD.33,34
There are some limitations to this review. We 
searched several databases to identify articles, 
but it is possible that the search was not exhaus-
tive. We included Google Scholar, as although it 
lacks the ability to reproduce searches, we con-
sidered it may assist in locating non-indexed arti-
cles which could otherwise be missed by other 
databases. The tools used to measure QOL and 
functionality varied; hence meta-analysis was not 
feasible for these outcomes. The approach to 
identify PIMs was not uniform across the studies 
either. For instance, studies used explicit criteria 
such as STOPPFrail and STOPP, or a list of pre-
determined medications or an algorithm to iden-
tify PIMs. The review contained only five studies, 
and they mostly had high attrition rates leading 
to loss of statistical power. This suggests that 
multi-centre studies with a larger sample size are 
necessary to build a valid estimate of the impact 
on health outcomes. It is also important to note 
that the outcomes were not the consequence of 
deprescribing of a single medication or exclu-
sively DPMs. It also suggests that deprescribing 
studies focusing only on DPMs are rare in the 
literature. It would be worth exploring this area 
further, as deprescribing DPMs are often avoided 
by clinicians and patients due to uncertainty 
around the likely adverse events.
Conclusion
This review suggests that deprescribing interven-
tions involving DPMs for older people with LLIs 
and LLE are rare in the literature, but there is 
some evidence that they can lower the risk of 
mortality and referral to acute care facilities. 
However, there is insufficient evidence to estab-
lish its impact on other outcomes, such as health 
service utilisation and adverse events. Reliable 
conclusions on whether deprescribing signifi-
cantly improves or worsens QOL, physical or 
cognitive functions were precluded by the hetero-
geneity in their assessment tool, medications 
deprescribed and high sample attrition. More 
studies with a larger sample size, a focus on 
DPMs, and clear identification of LLE and EOL 
profiles of older participants are needed to con-
firm these findings further.
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